Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary…
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
December 02, 2024 17:06 ET | Source: Molecular Templates, Inc. AUSTIN, Texas,…